LAUREN ESCHMANN: Open Payments
NPI 1316475734 · AMERICUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 47 payments from 13 companies in 2025. Trend: 2023 $461 · 2024 $652 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $210 |
| Novo Nordisk Inc | 16 | $184 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| ABBVIE INC. | 3 | $64 |
| Lilly USA, LLC | 2 | $43 |
| Amgen Inc. | 2 | $28 |
| Ardelyx, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
Products named: TRELEGY ELLIPTA, Ozempic, Rybelsus, AIRSUPRA, VRAYLAR, OTEZLA, IBSRELA, QULIPTA.
Industry payments across GA — which companies pay providers there.
